Neonatal Thrombocytopenia & Platelet Transfusion – An Update

Dr V C Manoj Assoc Professor & Head Dept of Neonatology Jubilee Mission Medical College & Research Institute Thrissur, Kerala

Scope

- 1. How good is the **Definition** of Thrombocytopenia in neonates?
- 2. What are the **differences between neonatal and adult** thrombopoiesis?
- 3. What is the **Diagnostic Approach**?
- 4. What are the current **guidelines for Platelet Transfusion**?



- 36 weeks late preterm SGA 2.1 kg male infant born vigorous and roomed in with mother, noticed to be lethargic on day 3 and investigated:
- Haemogram: Hb: 15, PCV: 46, TLC: 9600, Platelet Count: 55,000
- CRP: Neg, Blood Culture: Sterile

How do we manage this baby?



Defining Thrombocytopenia

- A symptom of a variety of congenital or acquired conditions in the neonatal period
- Platelet count <150,000 /uL
 - Mild Thrombocytopenia:100-150,000
 - Moderate: 50-99,000
 - Severe: <50,000
- Basis:
 - Pl production starts in fetus @ 5 wks
 - Count reaches adult level by 22 wks

Therefore traditionally, Neonatal value = Adult Value

Neonate = Adult ?

Challenging the Definition in Neonates

Recent large population study involving 47 291 neonates in 8 hospitals in US:

Lower limit of platelet

late preterm & term: 123,000/uL

32 weeks': 104,000 /UI

Significance ?

Wiedmeier SE et al, Platelet reference ranges for neonates, defined using data from over 47,000 patients in a multihospital healthcare system. J Perinatol. 2009;29(2):130-136.

Magnitude of the Problem

- ~18-32% of infants admitted to NICU
- more preterm infants.
- Increased risk for
 - ICH,
 - mortality, and
 - long term neurodevelopmental disability.

Platelet production:

All blood cells originate from stem cells in the red bone marrow



Platelets: tiny cellular fragments produced by megakaryocytes Short half life in circulation (7 - 10 days)



Production of Thrombopoietin (Tpo): Less in neonates





- Production of Thrombopoietin (Tpo)
- 2. Proliferation of megakaryocytes progenitors

3. Megakaryocyte maturation

- Increase in nuclear ploidy (the number of sets of chromosomes in a given cell)
- Generation of large polyploid (8N–64N) megakaryocytes
 - more in number but
 smaller and
 have lower ploidy than adults



- Production of Thrombopoietin (Tpo)
- 2. Proliferation of megakaryocytes progenitors
- 3. Megakaryocyte maturation

4. Development and release of new platelets.

by bursting of megakaryocyte

Response to increased platelet demand:



Adult BM: first

increases the MK size and ploidy and then increases the MK number

Limitation in

Neonates: can increase the number, but not the size of their MKs

Ma DC, Sun YH, Chang KZ, Zuo W. Developmental change of megakaryocyte maturation and DNA ploidy in human fetus. *Eur J Haematol. 1996;57(2):121-127*

Various Factors Influence Platelet Production:



Measures of platelet production like serum Tpo or reticulate platelet % (RP%)

- not reliable in the neonates!

How do I approach a neonate with thrombocytopenia?

Thrombocytopenia – 3 Periods of Presentation

Time of Onset	Туре
Fetal	 Immune: Alloimmune (NAIT) / Autoimmune Congenital Infections (TORCH, HIV) Chromosomal (Aneuploidy)
Early (<72 hrs)	 All above Placental Insufficiency (Eg: IUGR) Asphyxia Sepsis (DIC)
Variable (Early/Late)	 Sepsis Thrombosis Vascular tumor Metabolic (Proprionic acidemia, methylmalonic acidemia) ECMO
Late (>72 hrs)	 •NEC •Drug Induced (Penicillin and derivatives, vancomycin, metronidazole, Phenytoin, phenobarbital)

Early Onset <72 hrs

Well Baby:

- IUGR;
- Autoimmune thrombocytopenia
 - Mild to moderate thrombocytopenia
 - Nadir on postnatal day 4-5
 - Usually resolves by 7-10 days.

Sick Baby:

• Neonatal Alloimmune Thrombocytopenia (NAIT)

Variable (Sick / Well:

• Sepsis (Bacterial or viral), TORCH, DIC

Neonatal Autoimmune Thrombocytopenia

- Early onset
- Moderate severity
- Maternal history: +/-
 - Usually H/O ITP or autoimmune disease (2 in 1000 pregnancies)
 - Any infant born to a mom with autoimmune disease should have a platelet count (10%).
 - Sometimes Presenting sign of maternal autoimmune disease

Any mother having a neonate with thrombocytopenia should have a platelet count!

- Treatment: +/- (IVIG, Platelet transfusion)
- Evaluate for ICH (~1%).
- Lasts from days to months.

Neonatal Alloimmune Thrombocytopenia (NAIT)

- Severe (<50,000)
- Increased risk for ICH (8-22%)
- Antenatal Presentation: ICH, severe hydrocephalus, hydrops fetalis.
- Incidence 1 in 1500 pregnancies

Neonatal Alloimmune Thrombocytopenia (NAIT)



•Due to maternal Ab (to paternal Ag) present in fetal platelets

- •Can occur in first pregnancy
- •Testing of Mother and Father for Human Platelet antigen (HPA 1a, 5b, and 15b)

- sixteen HPAs identified but only three cause 95% of the NAIT cases

Neonatal Alloimmune Thrombocytopenia (NAIT)

- Requires Transfusion
- Resolves within 2 weeks
- Platelet count: needs to be followed until normalized and stable.
- If persists longer may be a different diagnosis.
- Monitoring for future pregnancies and possibly treatment with maternal IVIG/steroids.

Late-Onset Thrombocytopenia

• Ill Appearing:

- Sepsis (Viral & Fungal Earlier)
- NEC,
- IEM (Propionic Acidemia, isovaleric acidemia, methylmalonic acidemia, Gaucher Disease)

• Well Appearing:

- Drug induced,
- thrombosis,
- Fanconi's Anemia

The bleeding pattern

- Mucocutaneous.
- Petechiae, bruises, or bleeding from the mucous membranes
- Look out for: IVH / ICH!

Physical Exam

Keeping in Mind:

- 1. Time of onset: early & late
- 2. Gestational age: Term Vs preterm

3. Possible underlying mechanism

(consumption, increased destruction, decreased production), Due to maternal or infant factors or individualized to the particular infant.

- Ill or Well
- Petechia, bruising
- Fontonelle
- Liver size
- Abdominal masses (renal vein thrombosis)
- Dysmorphic features
- Forearm or thumb abnormalities (TAR syndrome or Fanconi anemia)

When do we need to treat?

Diagnostic approach



NeoReviews Vol.14 No.2 February 2013

Diagnostic approach



Diagnostic approach



When is the right time to transfuse Platelets?



Platelet transfusion thresholds selected by neonatologists in German-speaking European countries versus U.S. neonatologists in 2 different clinical scenarios!

Transfusion 2011;51:2636–7

When is the right time ???

Various prospective, observational trials strongly suggest that factors other than the platelet count determine the risk for major ICH!!

Platelet Count and Risk of Bleeding (US)

Risk:

- 100,000 20,000/uL: Minimal or mild risk of bleeding
- **20,000** 5,000/uL: Moderate Risk
- <5,000/ UI: severe Risk

Transfusion Threshold:

- Lower for preterm (Higer incidence IVH & "immaturity of the hemostatic system") - 50,000/uL ?
- When platelets < 30,000/UI: Trauma & stress of birth can precipitate ICH

Defining Threshold for Transfusion: (UK)

- < 150000 vs <50,000 no differences in freq or severity of ICH (Andrew et al 1993)
- Transfuse platelets: (volume reduction not necessary)

 www.eduction.com
 www.eduction.com
 www.eduction.com
 www.eduction.com
 www.eduction.com
 www.eduction.com
 www.eduction.com
 <a href="https://wwww
 - <50,000: Ill term / preterm (<33weeks) in 1st week of age.
 - <30,000: stable term / preterm > 1 week of age (Murray et al 2002: no major hemorrhage in infants if platelets >30,000)

NAIT: Management Guidelines:

- If platelets <50,000- Suggest cerebral imaging (US, MRI)
- Transfuse platelets:
 - trial of random donor platelets first.
 - If ineffective: Antigen negative platelets should be used (maternal platelets or known PL A1 or PL A5 negative platelets)
- Consider IVIG 1g/kg q 24hrs x 2 doses (+/- in combination with random donor transfusions)
- Consider **methylprednisolone** (1mg/kg q 8hrs) with IVIG.

Before deciding to transfuse

- Any doubt repeat sample
 - Errors from improper collection or unrecognized platelet clumping
- Blood culture +/- antibiotics depending on history, clinical picture and severity.
- Review peripheral smear and MPV
 - (Jacobsen and Fechtner syndromes present with large platelets and Wiskott-Aldrich syndrome and X-linked thrombocytopenia present with small platelets)

Remember when you Transfuse

- **Dose: 10-15ml/kg** random-donor platelets
 - Either CMV neg or leukoreduced
 - Irradiation to reduce GVHD
- Adv Effects: Platelet transfusions associated with TRALI (Transfusion Related Acute Lung Injury) and increased mortality ??
- Multiple Transfusion Requirement:
 - on a weekly basis decreased platelet production (congenital amegakaryocytic thrombocytopenia)
 - every 1-2 days increased platelet consumption.

Unanswered Questions !!



Which is more suitable platelet for transfusion in neonates?

Closure times after stimulation with CT-EPI (closure time epinephrine) –

Significantly shorter in neonatal blood "transfused" in vitro with adult platelets compared with blood "transfused" with neonatal platelets.

Ferrer-Marin F, Chavda C, Lampa M, Michelson AD, Frelinger Iii AL, Sola-Visner M. Effects of in-vitro adult platelet transfusions on neonatal hemostasis. J **Current Research:**

PlaNet-2 study

Ongoing RCT comparing two different platelet transfusion thresholds and aims to establish whether a lower platelet transfusion threshold is as good as a higher threshold in preterm infants < 34 weeks POG

Randomisations to date = 532 / 660 Platelet transfusion cut off: **Arm A : < 25; Arm B < 50** Primary Outcome: Death or severe IVH in 1ST 28 days

Dr Simon Stanworth, et al, University of Cambridge.



Thank you!

jubileenicu@gmail.com,



Genetic Disorders Associated With Thrombocytopenia

•	Chromosomal: Trisomy 13		Aplasia cutis, CHD, cleft lip and palate, polydactyly			
•	Trisomy 18		IUGR, CHD, rocker-bottom feet, overlapping digits, hypertelorism, small mouth, clinodactyly			
•	Trisomy 21		CHD, single palmar crease, hypotonia, short neck, w/ redundant posterior folds			
•	Turner syndrome		CHD, cubitus valgus, webbed posterior neck, broad chest , with wide-spaced nipples,lower extremity edema			
•	11 q terminal disorder CHD, GU anon		nalies, facial anomalies, abnl brain imaging, limb anomalies			
	(Jacobsen syndrome)					
•	<u>Familial :</u> May-Hegglin anomaly (Sebastian syndrome)		Giant platelets, neutrophilic inclusions			
•	Fechtner syndrome		Giant platelets, sensorineural hearing loss, cataracts, nephritis, neutrophilic inclusions			
•	Bernard-Soulier syndrome		Anemia, genitourinary abnormalities (cryptorchidism)			
•	Congenital amegakaryocytic thrombocytopenia vertebral ano		Abnl head size and shape, developmental delay, CHD, cleft and high-arched palate, abnormal kidneys, optic atrophy, valgus and varus deformities, omalies,coloboma, scoliosis, absent bone marrow megakaryocytes			
•	Wiscott-Aldrich syndrome		Immunodeficiency, small platelets, eczema			
•	Amegakaryocytic thrombocytopenia	Restricted forearm pronation, proximal radioulnar synostosis in forearm, and radioulnar synostosis absent bone marrow megakaryocytes				
•	Fanconi anemia		Hypopigmented and hyperpigmented skin lesions, urinary tract abnormalities, microcephaly, upper extremity radial-side abnormalities involving the thumb, pancytopenia (usually with onset in childhood)			
•	Thrombocytopenia and absent radii	Shortened/absent radii bilaterally, nml thumbs, ulnar and hand abnormalities, abnormalities of the humerus, CHD, eosinophilia, leukemoid reaction				
•	Neonatal primary hemophagocytic lymphohistiocytosis Fever, HSM, hyperferritemia, hypertriglyceridemia, hypofibrinogenemia					
•	<u>Metabolic:</u>					
•	Propionic acidemia, methylmalonic acidemia		FTT, developmental delay, ketoacidosis, hyperglycinemia, hyperammonemia			
•	• Isovaleric acidemia		Odor of sweaty feet, poor feeding, hypotonia, hyperammonemia, metabolic acidosis			
•	Gaucher disease		Hepatosplenomegaly, Gaucher cells in bone marrow			





Blood Clot





41



Specific Illnesses and Patterns Associated With Neonatal Thrombocytopenia

The second second		and the second se		
caredonies	STINADES	Differential Diagnoses (Where Applicable)	beverity	Onset
Immune	Alloimmune	Neonatal alloimmune thrombocytopenia	Severe	Enriv
	Autoimmune	Maternal IIP, lupus, other collagen vescular disorder	Severe-moderate	Early
Infectious	Bacteria)	68%, Gram-negative rods, Stanhylococcus, etc.	Variable	Variable
	Viral	CMV, HSV, HIV, enternythises	Variable	Usually early
	fungal	Candida, other	Avere	Usually early
	Parasite	Tozoplasmosis	Variable	Farly
Insufficiency		Precclampsia, ectampsia, chronic hypertension	Mild-moderate	Early
		Intrauterine growth restriction due	Mild-moderate	Early
DIC		Asphyzla	Severe	Early
		Sepsis	Severe	Variable
		Congenital TTP (rare)	Severe	Variable
Genetic disorders	Chromosomal	Trisomy 13, Trisomy 18, Trisomy 21, Tumer syndrome, Jacobsen syndrome	Variable	Early
	Femiliel	Macrothrombocytopenias, Wiskott-Aldrich syndrome, X-linked thrombocytopenias, Amegakaryocytic thrombocytopenia, TAR, Fanconi anemia*	Variable	Early
	Metabolic	Proprionic seldemis, methylmsionic	Mild-moderate	Variable
Medication Induced	Antibiotics	Penicillin and derivatives, vancomycin, metronidazole, etc.	Variable	Late
	Heparin		Variable:	1.ste
	Anticonvulsants	Phenytoin, phenobarbital	Variable	Late
	H=2 receptor antigonists		Variable	Late
Miscellaneous	Thrombosis	RVT, line-associated thrombosis, segittal sinus thrombosis	Moderate	Variable
	Vascular tumor	Kasabach Kasabach-Merritt, hepatle hemangloendothelioma	Moderate	Variable
	NEC	The second second second	Severe-moderate	thusly late
	ECMO		Variable	Variable

Alex Berlinbale and Alexandre and A